Balancing Treatment Efficacy with Toxicity in Metastatic RCC

David Aggen, MD, PhD, describes the challenges of balancing treatment efficacy versus toxicity and tolerability in patients with kidney cancer.

Related Videos
Noa Biran, MD, an expert on multiple myeloma
Experts on multiple myeloma
Experts on multiple myeloma
Experts on multiple myeloma
Experts on breast cancer
Experts on breast cancer
Experts on multiple myeloma
Experts on multiple myeloma
Experts on breast cancer
Hope S. Rugo, MD, an expert on breast cancer
Related Content